Lung Cancer
Expert faculty discuss antibody–drug conjugates (ADCs) in NSCLC with brain metastases, reviewing the clinical trial evidence, practical patient selection and sequencing alongside local CNS therapies, and the emerging pipeline of investigational ADCs.
The CHEST 2025 annual meeting brought together pulmonary, critical care, and sleep medicine experts to share emerging science, clinical insights, and forward-looking innovations shaping respiratory care. Through focused conversations with leaders across the field, these interviews highlight practical, practice-ready insights that clinicians can bring directly to patient care.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
It is my great pleasure to introduce touchREVIEWS in Respiratory & Pulmonary Diseases, Volume 10, Issue 1, 2025. This issue brings together a collection of timely and thought-provoking articles addressing key challenges and emerging innovations across the spectrum of respiratory and pulmonary care. ...
Despite significant advances over the years in cancer care, lung cancer unfortunately remains the leading cause of cancer-related mortality and one of the overall leading causes of death in the USA.1Â Understanding the complex interaction between our patients and their ...
Lung cancer remains the leading cause of cancer mortality and the second-most common cancer globally. In the USA, there were 238,340 new cases of lung cancer in 2023, according to the American Cancer Society.1 Worldwide, 2.2 million new cases were reported in 2020.2 Although ...
The American Lung Association (ALA) just completed their newly piloted freedom from smoking program curriculum, tailored to black communities 'Freedom From Smoking®: My Glory. My Journey. Living a Tobacco-Free Life'. With the pilot complete, the team at HMA has been sharing these successes with local organizations and health systems in hopes to gain traction and interest to expand the program throughout the black community.
July saw important advances in respiratory medicine, including new drug approvals and promising clinical trial results. Notable progress was made in treatments for lung cancer, cystic fibrosis, and pulmonary arterial hypertension, reflecting ongoing efforts to address challenging respiratory conditions. These developments highlight a dynamic period of innovation with the potential to improve patient outcomes and expand therapeutic options.
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!
Explore expert perspectives from ATS 2025 with our exclusive interview series. Discover key advances in respiratory care, including updates on COPD, ILD, ventilation strategies, and emerging therapies. Stay informed with concise, clinically relevant insights tailored for healthcare professionals on touchRESPIRATORY.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this interview, Dr Mural Quadros (St John’s University, New York, USA) discusses her presentation from the ATS International Conference in San Francisco, on a preclinical study evaluating inhaled osimertinib for malignant pleural mesothelioma (MPM). The research highlights the use of PLGA nanoparticles to deliver the drug directly to the lungs, offering a non-invasive, targeted alternative to current treatment options.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
